Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088512 · Präparat HOS-083663
Drugs by Therapeutic Area
Interaction Recommendation
Geometric mean change (%) concerning co-
(Possible mechanism) administration
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Didanosine /Zidovudine Interaction not studied.
Stavudine/Lamivudine Interaction not studied. Combination not
Stavudine/Zidovudine In vitro antagonism of anti-HIV recommended.
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Lamivudine Interaction not studied. As only limited data available
Atovaquone/Zidovudine Zidovudine AUC 33% the clinical significance is
(750 mg twice daily with Atovaquone AUC unknown.
food/200 mg thrice daily)
Clarithromycin/Lamivudine Interaction not studied. Separate administration of
Clarithromycin/Zidovudine Zidovudine AUC 12% Combivir and clarithromycin
(500 mg twice daily/100 mg by at least 2 hours
every 4 hours)
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% No Combivir dosage
(Co-trimoxazole)/Lamivudine adjustment necessary, unless
(160 mg/800 mg once daily for Trimethoprim: AUC patient has renal impairment
5 days/300 mg single dose) Sulfamethoxazole: AUC (See Section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) stavudine (HOS-088080) atovaquone (HOS-086266) clarithromycin (HOS-084517) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage ef0dd78ec8fb1f808137e8f5128b1cd7fa4540efa9cc39a15103836ffbdd97d9 · Zeichen 1146–3116 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-108560 · Präparat HOS-093047
Drugs by Therapeutic Area Interaction Recommendation
Geometric mean change concerning co-
(%) administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Didanosine/Zidovudine Interaction not studied.
Stavudine/Abacavir Interaction not studied. Combination not
Stavudine/Lamivudine Interaction not studied. recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 25e2eda4712b7995d43a3cb14050be9aa438e6a4898bdc14db6c4e7477aa31e8 · Zeichen 1694–2450 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-108561 · Präparat HOS-093047
8
Stavudine/Zidovudine In vitro antagonism of anti-HIV
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Abacavir Interaction not studied. As only limited data available
Atovaquone/Lamivudine Interaction not studied. the clinical significance is
Atovaquone/Zidovudine Zidovudine AUC 33% unknown.
(750 mg twice daily with Atovaquone AUC
food/200 mg thrice daily)
Clarithromycin/Abacavir Interaction not studied. Separate administration of
Clarithromycin/Lamivudine Interaction not studied. Trizivir and clarithromycin by
Clarithromycin/Zidovudine Zidovudine AUC 12% at least 2 hours
(500 mg twice daily/100 mg
every 4 hours)
Trimethoprim/sulfamethoxazole Interaction not studied. No Trizivir dosage adjustment
(Co-trimoxazole)/Abacavir necessary, unless patient has
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% renal impairment (See Section
(Co-trimoxazole)/Lamivudine 4.2).
(160mg/800mg once daily for 5 Trimethoprim: AUC
days/300mg single dose) Sulfamethoxazole: AUC When concomitant
administration with co-
(organic cation transporter trimoxazole is warranted,
inhibition) patients should be monitored
Trimethoprim/sulfamethoxazole Interaction not studied. clinically. High doses of
(Co-trimoxazole)/Zidovudine trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) stavudine (HOS-088080) atovaquone (HOS-086266) clarithromycin (HOS-084517) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 71bfdfc92b9301a18965d48965dbae21382ab47ace7b98ce7ba0a04318a98c78 · Zeichen 2506–4852 im Abschnitt
Wechselwirkungen · Pegasys
Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 17
HOS-109815 · Präparat HOS-093265
No apparent evidence of drug interaction was observed in 47 HIV-HCV co-infected patients who
completed a 12-week pharmacokinetic substudy to examine the effect of ribavirin on the intracellular
phosphorylation of some nucleoside reverse transcriptase inhibitors (lamivudine and zidovudine or
stavudine). However, due to high variability, the confidence intervals were quite wide. Plasma
exposure of ribavirin did not appear to be affected by concomitant administration of nucleoside
reverse transcriptase inhibitors (NRTIs).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080) ribavirin (HOS-088127)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 21c4b0d46fb6c2b69cb26b6685a1fc19babd245338fb29f0f1f06a1874a6027d · Zeichen 3177–3701 im Abschnitt
Wechselwirkungen · Pegasys
Pegasys 180 micrograms solution for injection · Abschnitt 4.5 · PDF-Seite 55
HOS-109875 · Präparat HOS-093265
No apparent evidence of drug interaction was observed in 47 HIV-HCV co-infected patients who
completed a 12-week pharmacokinetic substudy to examine the effect of ribavirin on the intracellular
phosphorylation of some nucleoside reverse transcriptase inhibitors (lamivudine and zidovudine or
stavudine). However, due to high variability, the confidence intervals were quite wide. Plasma
exposure of ribavirin did not appear to be affected by concomitant administration of nucleoside
reverse transcriptase inhibitors (NRTIs).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zidovudine (HOS-085837) stavudine (HOS-088080) ribavirin (HOS-088127) lamivudine (HOS-085829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 21c4b0d46fb6c2b69cb26b6685a1fc19babd245338fb29f0f1f06a1874a6027d · Zeichen 3179–3703 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-112069 · Präparat HOS-093615
The mechanism of interaction between
atazanavir and ritonavir is CYP3A4
inhibition.
Indinavir Indinavir is associated with indirect Co-administration of REYATAZ
unconjugated hyperbilirubinaemia due to and indinavir is not recommended
inhibition of UGT. (see section 4.4).
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Lamivudine 150 mg twice daily No significant effect on lamivudine and Based on these data and because
+ zidovudine 300 mg twice daily zidovudine concentrations was observed. ritonavir is not expected to have a
(atazanavir 400 mg once daily) significant impact on the
pharmacokinetics of NRTIs, the co-
administration of these medicinal
products and REYATAZ is not
expected to significantly alter the
exposure of the co-administered
medicinal products.
Abacavir The co-administration of abacavir and
REYATAZ is not expected to significantly
alter the exposure of abacavir.
Didanosine (buffered tablets) Atazanavir, simultaneous administration Didanosine should be taken at the
200 mg/stavudine 40 mg, both with ddI+d4T (fasted) fasted state 2 hours after
single dose Atazanavir AUC: ↓87% (↓92% ↓79%) REYATAZ taken with food. The
(atazanavir 400 mg single dose) Atazanavir Cmax: ↓89% (↓94% ↓82%) co-administration of stavudine with
Atazanavir Cmin: ↓84% (↓90% ↓73%) REYATAZ is not expected to
significantly alter the exposure of
Atazanavir, dosed 1 hr after ddI+d4T stavudine.
(fasted)
Atazanavir AUC: ↔3% (↓36% ↑67%)
Atazanavir Cmax: ↑12% (↓33% ↑18%)
Atazanavir Cmin: ↔3% (↓39% ↑73%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) indinavir (HOS-084518) lamivudine (HOS-085829) zidovudine (HOS-085837) abacavir (HOS-088077) didanosine (HOS-085836) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e16bb7b3c75a72e29e2846a95fde7bf075f1035a1823dc0170957041762fa37d · Zeichen 9816–12649 im Abschnitt
Wechselwirkungen · Emtriva
Emtriva 200 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-112680 · Präparat HOS-093727
There are no clinically significant interactions when emtricitabine is co-administered with indinavir,
zidovudine, stavudine, famciclovir or tenofovir disoproxil fumarate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) zidovudine (HOS-085837) stavudine (HOS-088080) famciclovir (HOS-112681) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-18T12:34:00Z · SHA-256 4ee4f99346bca4db5449cf522784d6dbc4cba891b89d833a052a1c777428bfcb · Passage 6c342d77dc818f8e9fa800bf4110e0bafd7270bcfe7cd5d464a283fa842875e8 · Zeichen 491–662 im Abschnitt
Wechselwirkungen · Emtriva
Emtriva 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 18
HOS-112707 · Präparat HOS-093727
There are no clinically significant interactions when emtricitabine is co-administered with indinavir,
zidovudine, stavudine, famciclovir or tenofovir disoproxil fumarate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) zidovudine (HOS-085837) stavudine (HOS-088080) famciclovir (HOS-112681) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-18T12:34:00Z · SHA-256 4ee4f99346bca4db5449cf522784d6dbc4cba891b89d833a052a1c777428bfcb · Passage 6c342d77dc818f8e9fa800bf4110e0bafd7270bcfe7cd5d464a283fa842875e8 · Zeichen 491–662 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-114812 · Präparat HOS-094169
Mechanism unknown.
Emtricitabine Potential interactions with renal No dosage adjustment necessary
No interaction study transporters cannot be fully in patients with normal renal
performed excluded. function.
In case of concomitant
administration of emtricitabine
and Aptivus/ritonavir, renal
function should be evaluated
before initiating the co-
administration.
Lamivudine 150 mg BID No clinically significant No dosage adjustment necessary.
(TPV/r 750/100 mg BID) interaction is observed.
Stavudine No clinically significant No dosage adjustment necessary.
40 mg BID ≥ 60 kg interaction is observed.
30 mg BID < 60 kg
(TPV/r 750/100 mg BID)
Zidovudine 300 mg BID Zidovudine Cmax ↓ 49% The concomitant use of Aptivus,
(TPV/r 750/100 mg BID) Zidovudine AUC ↓ 36% co-administered with low dose
ritonavir with zidovudine is not
The clinical relevance of this recommended unless there are no
reduction has not been other available NRTIs suitable for
established, but may decrease patient management. In such
the efficacy of zidovudine. cases no dosage adjustment of
zidovudine can be recommended
Mechanism unknown. (see section 4.4).
Tenofovir 300 mg QD No clinically significant No dosage adjustment necessary.
(TPV/r 750/200 mg BID) interaction is observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamivudine (HOS-085829) stavudine (HOS-088080) zidovudine (HOS-085837) tenofovir (HOS-088083) emtricitabine (HOS-085840) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage eddf8e6e82859b2c18f67a05da076a7a8f549e2631ec2ae24d486e7770ce66bb · Zeichen 6305–8506 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116342 · Präparat HOS-094447
11
Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir
may cause a modest decrease in on darunavir plasma
darunavir plasma concentrations. concentrations does not appear to
be clinically relevant. Boosted
PREZISTA and raltegravir can be
used without dose adjustments.
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and
400 mg once daily didanosine Cmin ND didanosine can be used without
didanosine Cmax ↓ 16% dose adjustments.
darunavir AUC ↔ Didanosine is to be administered
darunavir Cmin ↔ on an empty stomach, thus it
darunavir Cmax ↔ should be administered 1 hour
before or 2 hours after boosted
PREZISTA given with food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted
tenofovir Cmax ↑ 24% PREZISTA is given in
#
darunavir AUC ↑ 21% combination with tenofovir
#
darunavir Cmin ↑ 24% disoproxil, particularly in patients
# with underlying systemic or renal
darunavir Cmax ↑ 16%
disease, or in patients taking
(↑ tenofovir from effect on MDR-1
nephrotoxic agents.
transport in the renal tubules)
PREZISTA co-administered with
cobicistat lowers the creatinine
clearance. Refer to section 4.4 if
creatinine clearance is used for
dose adjustment of tenofovir
disoproxil.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with boosted
PREZISTA.
Abacavir Not studied. Based on the different Boosted PREZISTA can be used
Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose
Lamivudine zidovudine, emtricitabine, stavudine, adjustment.
Stavudine lamivudine, that are primarily renally
Zidovudine excreted, and abacavir for which PREZISTA co-administered with
metabolism is not mediated by CYP450, cobicistat lowers the creatinine
no interactions are expected for these clearance. Refer to section 4.4 if
medicinal compounds and boosted creatinine clearance is used for
PREZISTA. dose adjustment of emtricitabine or
lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) tenofovir alafenamide (HOS-110476) creatinine (HOS-086273) raltegravir (HOS-086187) didanosine (HOS-085836) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) cobicistat (HOS-088111) abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 512d9066057a9fd93eb4b013c0f43af18ef8a6621ab7ae5b2a63872300e65b37 · Zeichen 8755–13360 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-116511 · Präparat HOS-094447
53
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with
400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine
didanosine Cmax ↓ 16% can be used without dose
darunavir AUC ↔ adjustments.
darunavir Cmin ↔ Didanosine is to be administered
darunavir Cmax ↔ on an empty stomach, thus it
should be administered 1 hour
before or 2 hours after
PREZISTA/ritonavir given with
food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA
tenofovir Cmax ↑ 24% co-administered with low dose
#
darunavir AUC ↑ 21% ritonavir is given in combination
#
darunavir Cmin ↑ 24% with tenofovir disoproxil,
# particularly in patients with
darunavir Cmax ↑ 16%
underlying systemic or renal
(↑ tenofovir from effect on MDR-1
disease, or in patients taking
transport in the renal tubules)
nephrotoxic agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with PREZISTA
with low dose ritonavir.
Abacavir Not studied. Based on the different PREZISTA co-administered with
Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used
Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose
Stavudine lamivudine, that are primarily renally adjustment.
Zidovudine excreted, and abacavir for which
metabolism is not mediated by CYP450,
no interactions are expected for these
medicinal compounds and PREZISTA
co-administered with low dose ritonavir.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central
600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated
efavirenz Cmax ↑ 15% with increased exposure to
#
darunavir AUC ↓ 13% efavirenz may be indicated when
#
darunavir Cmin ↓ 31% PREZISTA co-administered with
# low dose ritonavir is given in
darunavir Cmax ↓ 15%
combination with efavirenz.
(↑ efavirenz from CYP3A inhibition)
(↓ darunavir from CYP3A induction)
Efavirenz in combination with
PREZISTA/ritonavir 800/100 mg
once daily may result in
sub-optimal darunavir Cmin. If
efavirenz is to be used in
combination with
PREZISTA/ritonavir, the
PREZISTA/ritonavir 600/100 mg
twice daily regimen should be used
(see section 4.4).
Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with
100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine
etravirine Cmax ↓ 32% 200 mg twice daily can be used
darunavir AUC ↑ 15% without dose adjustments.
darunavir Cmin ↔
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080) tenofovir alafenamide (HOS-110476) didanosine (HOS-085836) ritonavir (HOS-084521) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) emtricitabine (HOS-085840) efavirenz (HOS-087947) etravirine (HOS-088088)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f8ead3f953777de3c19f091bf055bc5528212e16095144f2b7b3940946af839d · Zeichen 6411–12375 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93–94
HOS-116603 · Präparat HOS-094447
93
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted
tenofovir Cmax ↑ 24% PREZISTA is given in
#
darunavir AUC ↑ 21% combination with tenofovir
#
darunavir Cmin ↑ 24% disoproxil, particularly in patients
# with underlying systemic or renal
darunavir Cmax ↑ 16%
disease, or in patients taking
(↑ tenofovir from effect on MDR-1
nephrotoxic agents.
transport in the renal tubules)
PREZISTA co-administered with
cobicistat lowers the creatinine
clearance. Refer to section 4.4 if
creatinine clearance is used for
dose adjustment of tenofovir
disoproxil.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with boosted
PREZISTA.
Abacavir Not studied. Based on the different Boosted PREZISTA can be used
Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose
Lamivudine zidovudine, emtricitabine, stavudine, adjustment.
Stavudine lamivudine, that are primarily renally
Zidovudine excreted, and abacavir for which PREZISTA co-administered with
metabolism is not mediated by CYP450, cobicistat lowers the creatinine
no interactions are expected for these clearance. Refer to section 4.4 if
medicinal compounds and boosted creatinine clearance is used for
PREZISTA. dose adjustment of emtricitabine or
lamivudine.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central
600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated
efavirenz Cmax ↑ 15% with increased exposure to
#
darunavir AUC ↓ 13% efavirenz may be indicated when
#
darunavir Cmin ↓ 31% PREZISTA co-administered with
# low dose ritonavir is given in
darunavir Cmax ↓ 15%
combination with efavirenz.
(↑ efavirenz from CYP3A inhibition)
(↓ darunavir from CYP3A induction)
Efavirenz in combination with
PREZISTA/ritonavir 800/100 mg
once daily may result in
sub-optimal darunavir Cmin. If
efavirenz is to be used in
combination with
PREZISTA/ritonavir, the
PREZISTA/ritonavir 600/100 mg
twice daily regimen should be used
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) cobicistat (HOS-088111) creatinine (HOS-086273) emtricitabine (HOS-085840) tenofovir alafenamide (HOS-110476) abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 08a2b9d3e388606555bc20885d7218a313fdbcadf305f03e98e87336cbf0f0e8 · Zeichen 10372–15436 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119733 · Präparat HOS-095005
Table 2: Interactions and dose recommendations with other medicinal products
Medicinal products by Effects on drug levels Recommendations
therapeutic areas Least Squares Mean Ratio concerning
(90% CI; 1.00 = No effect) co-administration
ANTI-INFECTIVES
Antiretrovirals
NRTIs
Didanosine didanosine No significant effect on
400 mg once daily AUC ↔ 0.99 (0.79-1.25) didanosine and etravirine PK
Cmin ND parameters is seen.
Cmax ↔ 0.91 (0.58-1.42) INTELENCE and didanosine
etravirine can be used without dose
AUC ↔ 1.11 (0.99-1.25) adjustments.
Cmin ↔ 1.05 (0.93-1.18)
Cmax ↔ 1.16 (1.02-1.32)
Tenofovir disoproxil tenofovir No significant effect on
245 mg once dailyb AUC ↔ 1.15 (1.09-1.21) tenofovir and etravirine PK
Cmin ↑ 1.19 (1.13-1.26) parameters is seen.
Cmax ↑ 1.15 (1.04-1.27) INTELENCE and tenofovir
etravirine can be used without dose
AUC ↓ 0.81 (0.75-0.88) adjustments.
Cmin ↓ 0.82 (0.73-0.91)
Cmax ↓ 0.81 (0.75-0.88)
Other NRTIs Not studied, but no interaction expected based INTELENCE can be used
on the primary renal elimination route for other with these NRTIs without
NRTIs (e.g., abacavir, emtricitabine, dose adjustment.
lamivudine, stavudine and zidovudine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) abacavir (HOS-088077) emtricitabine (HOS-085840) lamivudine (HOS-085829) stavudine (HOS-088080) zidovudine (HOS-085837) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage f29152615b96440b7358c56a91ccfc38d2ce96481ae99b250502680fed6f7a18 · Zeichen 1742–3928 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-129249 · Präparat HOS-096703
Emtricitabine, didanosine, Interaction not studied Triumeq is not recommended for use in
stavudine, zidovudine. combination with emtricitabine
containing products, since both
lamivudine (in Triumeq) and
emtricitabine are cytidine analogues (i.e.
risk for intracellular interactions, (see
section 4.4))
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir ↑ No dose adjustment is necessary.
AUC ↑ 91%
Cmax ↑ 50%
Cτ ↑ 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) protease (HOS-085623) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 3bf10bb4dbff2b9e9a1f2913477a1a9b99c0f91eb5eef71b2dcdb54e9afc81f8 · Zeichen 10865–11769 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 47
HOS-129348 · Präparat HOS-096703
Emtricitabine, didanosine, Interaction not studied Triumeq is not recommended for use in
stavudine, zidovudine. combination with emtricitabine
containing products, since both
lamivudine (in Triumeq) and
emtricitabine are cytidine analogues (i.e.
risk for intracellular interactions, (see
section 4.4))
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir ↑ No dose adjustment is necessary.
AUC ↑ 91%
Cmax ↑ 50%
Cτ ↑ 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) protease (HOS-085623) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 3bf10bb4dbff2b9e9a1f2913477a1a9b99c0f91eb5eef71b2dcdb54e9afc81f8 · Zeichen 9175–10079 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-134477 · Präparat HOS-097580
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
HIV ANTIRETROVIRALS
Integrase strand transfer inhibitors
Dolutegravir dolutegravir AUC ↓ 22% dolutegravir Darunavir co-administered with low
C24h ↓ 38% dolutegravir Cmax ↓ 11% dose ritonavir and dolutegravir can
darunavir ↔* be used without dose adjustment.
* Using cross-study comparisons to
historical pharmacokinetic data
Raltegravir Some clinical studies suggest At present the effect of raltegravir
raltegravir may cause a modest on darunavir plasma concentrations
decrease in darunavir plasma does not appear to be clinically
concentrations. relevant. Darunavir co-administered
with low dose ritonavir and
raltegravir can be used without dose
adjustments.
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% Darunavir co-administered with low
400 mg once daily didanosine Cmin ND dose ritonavir and didanosine can
didanosine Cmax ↓ 16% be used without dose adjustments.
darunavir AUC ↔ Didanosine is to be administered on
darunavir Cmin ↔ an empty stomach, thus it should be
darunavir Cmax ↔ administered 1 hour before or 2
hours after darunavir/ritonavir given
with food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when darunavir co-
tenofovir Cmax ↑ 24% administered with low dose
#
darunavir AUC ↑ 21% ritonavir is given in combination
#
darunavir Cmin ↑ 24% with tenofovir disoproxil,
#
darunavir Cmax ↑ 16% particularly in patients with
underlying systemic or renal
(↑ tenofovir from effect on MDR-1
disease, or in patients taking
transport in the renal tubules)
nephrotoxic agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide
is 200/10 mg once daily when used
with darunavir with low dose
ritonavir.
Abacavir Not studied. Based on the different Darunavir co-administered with low
Emtricitabine elimination pathways of the other dose ritonavir can be used with
Lamivudine NRTIs zidovudine, emtricitabine, these NRTIs without dose
Stavudine stavudine, lamivudine, that are adjustment.
Zidovudine primarily renally excreted, and
abacavir for which metabolism is not
mediated by CYP450, no interactions
are expected for these medicinal
compounds and darunavir co-
administered with low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir alafenamide (HOS-110476) tenofovir disoproxil (HOS-108843) abacavir (HOS-088077) tenofovir (HOS-088083) lamivudine (HOS-085829) emtricitabine (HOS-085840) dolutegravir (HOS-089992) ritonavir (HOS-084521) raltegravir (HOS-086187) didanosine (HOS-085836) zidovudine (HOS-085837) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage ccba4214faa97b5376d4e4a8ce74635a775924857bc2c674b7028ff519f04d29 · Zeichen 4790–9569 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50–51
HOS-134609 · Präparat HOS-097580
50
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% Boosted darunavir and didanosine
400 mg once daily didanosine Cmin ND can be used without dose
didanosine Cmax ↓ 16% adjustments.
darunavir AUC ↔ Didanosine is to be administered on
darunavir Cmin ↔ an empty stomach, thus it should be
darunavir Cmax ↔ administered 1 hour before or 2 hours
after boosted darunavir given with
food.
Tenofovir disoproxil 245 mg tenofovir AUC ↑ 22% Monitoring of renal function may be
once daily‡ tenofovir Cmin ↑ 37% indicated when boosted darunavir is
tenofovir Cmax ↑ 24% given in combination with tenofovir
#
darunavir AUC ↑ 21% disoproxil, particularly in patients
#
darunavir Cmin ↑ 24% with underlying systemic or renal
#
darunavir Cmax ↑ 16% disease, or in patients taking
nephrotoxic agents.
(↑ tenofovir from effect on MDR-1
transport in the renal tubules)
Darunavir co-administered with
cobicistat lowers the creatinine
clearance. Refer to section 4.4 if
creatinine clearance is used for dose
adjustment of tenofovir disoproxil.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide
is 200/10 mg once daily when used
with boosted darunavir.
Abacavir Not studied. Based on the different Boosted darunavir can be used with
Emtricitabine elimination pathways of the other these NRTIs without dose
Lamivudine NRTIs zidovudine, emtricitabine, adjustment.
Stavudine stavudine, lamivudine, that are
Zidovudine primarily renally excreted, and Darunavir co-administered with
abacavir for which metabolism is cobicistat lowers the creatinine
not mediated by CYP450, no clearance. Refer to section 4.4 if
interactions are expected for these creatinine clearance is used for dose
medicinal compounds and boosted adjustment of emtricitabine or
darunavir. lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) tenofovir alafenamide (HOS-110476) didanosine (HOS-085836) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) cobicistat (HOS-088111) creatinine (HOS-086273) abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 12f10221f64cd5bd996c35b7dbe8c441b3a4283b2a2e058c57f14f12c78125d7 · Zeichen 9327–13171 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-142822 · Präparat HOS-098886
7
Nevirapine/Dolutegravir Dolutegravir The recommended dose of dolutegravir
(Not studied, a similar is 50 mg twice daily when
reduction in exposure as co-administered with nevirapine. As
observed with efavirenz is Dovato is a fixed-dose tablet, an
expected, due to additional 50 mg tablet of dolutegravir
induction) should be administered, approximately
12 hours after Dovato for the duration of
the nevirapine co-administration (a
separate formulation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Rilpivirine/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 12%
Cmax 13%
Cτ 22%
Rilpivirine
Nucleoside reverse transcriptase inhibitors (NRTIs)
Tenofovir disoproxil Dolutegravir No dose adjustment is necessary when
AUC 1% Dovato is combined with tenofovir,
Cmax 3% didanosine, stavudine or zidovudine.
Cτ 8%
Tenofovir Dovato is not recommended for use in
combination with emtricitabine
containing products, since both
Emtricitabine, didanosine, Interaction not studied lamivudine (in Dovato) and
stavudine, tenofovir emtricitabine are cytidine analogues (i.e.
alafenamide, zidovudine risk for intracellular interactions), see
section 4.4.
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 91%
Cmax 50%
C 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) protease (HOS-085623) atazanavir (HOS-086180) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) nevirapine (HOS-088064) efavirenz (HOS-087947) rilpivirine (HOS-088090) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 3a54b7ec17f478707f317729fc54112d075d89e9ca126df050e9dd9dc88cd6d2 · Zeichen 7977–10650 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.